Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

9 Aug 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to Fibroblast Growth Factor Research
Share to IgG4-Related and Inflammatory Diseases

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31405822
DOI: 10.1016/s1470-2045(19)30412-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyPMID 31405822Read ↗

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.Semantic proximity Read ↗

EGFR antagonists in cancer treatment.Semantic proximity Read ↗

A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)Semantic proximity Read ↗

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesSemantic proximity Read ↗

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.Semantic proximity Read ↗

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.Semantic proximity Read ↗

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.Semantic proximity Read ↗

Low-Dosage Apatinib in Treating Advanced Pulmonary Adenocarcinoma With Kras Mutation After Osimertinib Resistance: A Case Report.Semantic proximity Read ↗

Dasatinib: a new step in molecular target therapySemantic proximity Read ↗

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.Semantic proximity Read ↗

The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.Semantic proximity Read ↗

Targeting Aberrant FGFR Signaling with Infigratinib Enhances the Efficacy of BTK/PI3K Inhibitors and Bendamustine in Lymphoma CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.